http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-201629100-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a8e20137e10efebd66f7b326dc42151 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-524 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-61 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2015-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_016721e5d687881be960e616939833e9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2a58606a34546a17403f620eccc9fbf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e04c496b198356807a87fc6c3144218 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_490a754a2e3f91e017353d647fd7079c |
| publicationDate | 2016-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | TW-201629100-A |
| titleOfInvention | Human IgG4 Fc polypeptide variant |
| abstract | The present invention relates to a human IgG4 Fc polypeptide variant, wherein the Fc polypeptide is prepared by replacing a portion of the N-terminus of the CH2 domain of human IgG4 with a portion of the CH2 domain of another immunoglobulin Fc, and also includes the polypeptide and organism. A chimeric polypeptide of an active molecule, a method of producing the polypeptide and the chimeric polypeptide, a nucleic acid molecule encoding the polypeptide and the chimeric polypeptide, an expression vector comprising the nucleic acid molecule, and a host cell comprising the expression vector. When the IgG4 Fc CH2 polypeptide variant of the invention is used, the half-life of the biologically active protein can be increased, but ADCC is not induced. Therefore, the variant can be effectively applied to different types of biologically active protein drugs having a short half-life in vivo. Moreover, it is possible to prepare a hydrophobic replacement region junction site without artificially mutating the immunoglobulin, thereby minimizing the non-specific immune response. |
| priorityDate | 2014-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1161.